Breast Cancer Research and Treatment

, Volume 62, Issue 1, pp 1–17 | Cite as

Chemoprevention of breast cancer

  • Powel H. Brown
  • Scott M. Lippman
Article

Abstract

Despite a recent trend toward improvement in the U.S. breast cancer mortality rate, breast cancer incidence (182,800 new cases anticipated in 2000) and mortality figures (over 40,800 anticipated deaths) remain the highest and second highest, respectively, of all cancers in U.S. women. In 1998, the selective-estrogen-receptor-modulator (SERM) tamoxifen achieved positive results in the Breast Cancer Prevention Trial (BCPT), leading to the Food and Drug Administration (FDA) approval of tamoxifen for risk reduction in women at high risk of breast cancer (the historic first FDA approval of a cancer preventive agent). This brought about a paradigm shift in new approaches for controlling breast cancer toward pharmacologic preventive regimens, called chemoprevention. This paper presents a comprehensive clinical review of breast cancer prevention study, highlighting issues of the extensive study of tamoxifen. These issues include the record of primary tamoxifen results in several breast-cancer risk-reduction settings (primary, adjuvant, and ductal carcinoma in situ [DCIS]); critical secondary BCPT risk-benefit findings (including quality of life issues) and their effects on counseling patients on use of tamoxifen for prevention; ethic minorities; optimal tamoxifen dose/duration; and potential impact on mortality and other issues involved with potential net benefit to society. Other breast-cancer chemoprevention issues reviewed here include women at high genetic risk (especially BRCA1 mutation carriers); raloxifene in breast cancer prevention; other SERMs; SERM resistance; and new agents and combinations currently in development. Very recent developments involving PPAR-γ ligands, COX-2 inhibitors, and RXR-ligands are discussed in the section on new drug development.

breast cancer prevention tamoxifen raloxifene SERMs retinoids 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7–33, 2000Google Scholar
  2. 2.
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al.: Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371–1388, 1998Google Scholar
  3. 3.
    Jordan VC, Morrow M: Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20: 253–278, 1999Google Scholar
  4. 4.
    Dhingra K: Antiestrogens–tamoxifen, SERMs and beyond. Invest New Drugs 17: 285–311, 1999Google Scholar
  5. 5.
    Lippman SM, Brown PH: Tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst 91: 1809–1819, 1999Google Scholar
  6. 6.
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351: 1451–1467, 1998Google Scholar
  7. 7.
    Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98–101, 1998Google Scholar
  8. 8.
    Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352: 93–97, 1998Google Scholar
  9. 9.
    Wolmark N, Dignam J, Fisher B: The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ductal carcinoma in situ (DCIS): preliminary results of NSABP protocol B-24. Breast Cancer Res Treat 50: Abstract 1, 1998Google Scholar
  10. 10.
    Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E et al.: Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project B-24 randomised controlled trial. Lancet 353: 1993–2000, 1999Google Scholar
  11. 11.
    Lippman SM, Lee JJ, Sabichi AL: Cancer chemoprevention: progress and promise. J Natl Cancer Inst 90: 1514–1528, 1998Google Scholar
  12. 12.
    Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609–1618, 1998Google Scholar
  13. 13.
    Jordan VC: Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J Natl Cancer Inst 90: 967–971, 1998Google Scholar
  14. 14.
    O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ et al.: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 90: 1552–1558, 1998Google Scholar
  15. 15.
    Narod S: Letter: Re: Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 91: 188, 1999Google Scholar
  16. 16.
    Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC et al.: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852–856, 1992Google Scholar
  17. 17.
    Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF et al.: Bone mass and the risk of breast cancer among postmenopausal women. N Engl J. Med 336: 611–616, 1997Google Scholar
  18. 18.
    Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B: Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Clin Oncol 17: 2659–2669, 1999Google Scholar
  19. 19.
    Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP et al.: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer Inst 82: 1327–1332, 1990Google Scholar
  20. 20.
    Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular systesm. N Engl J Med 340: 1801–1811, 1999Google Scholar
  21. 21.
    Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605–613, 1998Google Scholar
  22. 22.
    Yaffe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279: 688–695, 1998Google Scholar
  23. 23.
    Ganz PA, Day R, Ware JE Jr, Redmond C, Fisher B: Base-line quality of life assessment in the National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial. J Natl Cancer Inst 87: 1372–1382, 1995Google Scholar
  24. 24.
    Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG: American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 17: 1939–1955, 1999Google Scholar
  25. 25.
    Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91: 1829–1846, 1999Google Scholar
  26. 26.
    Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al.: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529–1542, 1996Google Scholar
  27. 27.
    Fisher B: National surgical adjuvant breast and bowel project breast cancer prevention trial: a reflective commentary. J Clin Oncol 5: 1632–1639, 1999Google Scholar
  28. 28.
    Rockhill B, Colditz G, Kaye J: Re: Tamoxifen prevention of breast cancer: an instance of the fingerpost [letter]. J Natl Cancer Inst 92: 657–658, 2000Google Scholar
  29. 29.
    Lippman SM, Brown PH: Response: Re: Tamoxifen prevention of breast cancer: an instance of the fingerpost [letter]. J Natl Cancer Inst 92: 658–659, 2000Google Scholar
  30. 30.
    Fisher B: Response: Re: Tamoxifen prevention of breast cancer: an instance of the fingerpost [letter]. J Natl Cancer Inst 92: 659–660, 2000Google Scholar
  31. 31.
    Phillips K, Glendon G, Knight JA: Putting the risk of breast cancer in perspective. N Engl J Med 340: 141–143, 1999Google Scholar
  32. 32.
    Page DL, Simpson JF: Ductal carcinoma in situ — The focus for prevention, screening, and breast conservation in breast cancer. N Engl J Med 340: 1499–1500, 1999Google Scholar
  33. 33.
    Fisher ER, Fisher B: Relation of a recurrent intraductal carcinoma (ductal carcinoma in situ) to the primary tumor. J Natl Cancer Inst 92: 288–289, 2000Google Scholar
  34. 34.
    Wilcken NR: Tamoxifen hits the target in situ. Lancet 12: 353, 1986–dy1987, 1999Google Scholar
  35. 35.
    Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B et al.: Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 17: 2633–2683, 1999Google Scholar
  36. 36.
    Taylor Al, Adams-Campbell LL, Wright JT Jr: Risk/benefit assessment of tamoxifen to prevent breast cancer – still a work in progress? [editorial]. J Natl Cancer Inst 91: 1792–1793, 1999Google Scholar
  37. 37.
    Taylor AL, Adams-Campbell LL, Wright JT Jr: Response: Re: Risk/benefit assessment of tamoxifen to prevent breast cancer – still a work in progress? [letter]. J Natl Cancer Inst 92: 574–575, 2000Google Scholar
  38. 38.
    McCaskill-Stevens W, Bryant J, Costantino J, Wickerham DL, Vogel V, Wolmark N et al.: Incidence of contralateral breast cancer (CBC), endometrial cancer (EC), and thromboembolic events (TE) in African American (AA) women receiving tamoxifen for treatment of primary breast cancer [abstract]. Proc ASCO 19: 70a, 2000Google Scholar
  39. 39.
    Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA: Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354: 1846–1850, 1999Google Scholar
  40. 40.
    Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Esaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475–1479, 1999Google Scholar
  41. 41.
    Loman N, Johannsson O, Bendahl PA, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83: 310–319, 1998Google Scholar
  42. 42.
    Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A et al.: Distinct molecular pathogeneses of earlyonset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59: 2011–2017, 1999Google Scholar
  43. 43.
    Hartmann J, Schaid D, Woods J, Crotty T, Myers J, Arnold P et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340: 77–84, 1999Google Scholar
  44. 44.
    Eisen A, Weber BL: Prophylactic mastectomy – The price of fear. N Engl J Med 340: 137–138, 1999Google Scholar
  45. 45.
    Brown P, Fuqua S, Allred C: Pathogenesis of estrogen receptor positive and negative breast cancer. In: Ethier SP, (ed). Contemporary Endocrinology: Endocrine Oncology. Totowa (NJ): Humana Press. p. 49–68, 2000Google Scholar
  46. 46.
    Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR et al.: BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284: 1354–1356, 1999Google Scholar
  47. 47.
    Osin P, Crook T, Powles T, Peto J, Gusterson B: Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers. Lancet 351: 1487, 1998Google Scholar
  48. 48.
    Jordan VC: How is tamoxifen's action subverted? J Natl Cancer Inst 92: 92–93, 2000Google Scholar
  49. 49.
    Radmacher MD, Simon R: Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors. J Natl Cancer Inst 92: 48–53, 2000Google Scholar
  50. 50.
    Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281: 2189–2197, 1999Google Scholar
  51. 51.
    Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A et al.: Raloxifene reduces incident primary breast cancers: integrated data from multicenter, double-blind, placebocontrolled, randomized trials in postmenopausal women. Breast Cancer Res Treat 50: Abstract 2, 1998Google Scholar
  52. 52.
    Lippman SM, Benner SE, Hong WK: Cancer chemoprevention. J Clin Oncol 12: 851–873, 1994Google Scholar
  53. 53.
    O'Shaughnessy J: Chemoprevention of breast cancer. JAMA 275: 1349–1353, 1996Google Scholar
  54. 54.
    Mehta RG, Williamson E, Patel MK, Koefflex HP: A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92: 418–423, 2000Google Scholar
  55. 55.
    Harris RE, Alshafie GA, Hussen A-I, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101–2103, 2000Google Scholar
  56. 56.
    Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM: Retinoid receptor-dependent and-independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 59: 14–18, 1999Google Scholar
  57. 57.
    Sun S-Y, Li W, Yue P, Lippman SM, Hong WK, Lotan R: Mediation of N-(4-hydroxyphenyl)retinamide-induced apoptosis in human cancer cells by different machanisms. Cancer Res 59: 2493–2498, 1999Google Scholar
  58. 58.
    Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847–1856, 1999Google Scholar
  59. 59.
    Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ et al.: Suppression of retinoic acid receptor beta in oral premalignant lesions and its upregulation by isotretinoin. N Engl JMed 332: 1405–1410, 1995Google Scholar
  60. 60.
    Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukmanji F et al.: Progressive decrease in nuclear retinoic acid receptor b messenger RNA level during breast carcinogenesis. Cancer Res 57: 4992–4996, 1997Google Scholar
  61. 61.
    Widschwendter M, Berger J, Daxenbichler G, Muller Holzner E, Widschwendter A, Mayr A et al.: Loss of retinoic acid receptor b expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue. Cancer Res 57: 4158–4161, 1997Google Scholar
  62. 62.
    Kuppumbatti YS, Bleiweiss IJ, Mandeli JP, Wasman S, Mira-Y-Lopez R: Cellular retinol-binding protein expression and breast cancer. J Natl Cancer Inst 92: 475–480, 2000Google Scholar
  63. 63.
    Spinella MJ, Dmitrovsky E: Aberrant retinoid signaling and breast cancer: the view from outside the nucleus. J Natl Cancer Inst 92: 438–440, 2000Google Scholar
  64. 64.
    Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) cause complete regression of mammary carcinoma. Cancer Res 58: 479–484, 1998Google Scholar
  65. 65.
    Bischoff ED, Heyman RA, Lamph WW: Effect of the retinoid X receptor-selective ligand LGD 1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 91: 2118, 1999Google Scholar
  66. 66.
    Nunez SB, Medin JA, Braissant O, Kemp L, Wahli W, Ozato K et al.: Retinoid X receptor and peroxisome proliferateractivated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol Cell Endocrinol 127: 27–40, 1997Google Scholar
  67. 67.
    Chen TK, Smith LM, Gebhardt D, Birrer MJ, Brown PH: Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog 15: 215–226, 1996Google Scholar
  68. 68.
    Smith LM, Birrer MJ, Stampher MR, Brown PH: Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res 57: 3046–3054, 1997Google Scholar
  69. 69.
    Yang LM, Kim HT, Munoz-Medellin D, Reddy P, Brown PH: Induction of retinoid resistance in breast cancer cells by overexpression of cJun. Cancer Res 57: 4652–4661, 1997Google Scholar
  70. 70.
    Yu W, Simmons-Menchaca M, You H, Brown PH, Birrer M, Sanders B, et al.: RRR-α-tocopheryl succinate induces prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. Mol Carcinog 22: 247–257, 1998Google Scholar
  71. 71.
    Smith LM, Wise SC, Hendricks DT, Sabichi AL, Brown PH, Birer MJ: cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18: 6063–6070, 1999Google Scholar
  72. 72.
    Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M et al.: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251–256, 1999Google Scholar
  73. 73.
    Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG et al.: Tamoxifen-stimulated breast tumor growth in vivo is associated with oxidative stress and increased AP-1 activity. J Natl Cancer Inst (in press)Google Scholar
  74. vn74.
    Yang L, Munoz-Medellin D, Kim HT, Ostrowski J, Reczek P, Brown PH: Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression. Breast Cancer Res Treat 56: 277–291, 1999Google Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Powel H. Brown
  • Scott M. Lippman

There are no affiliations available

Personalised recommendations